bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
0.295
-0.008 (-2.77%)
Nov 21, 2024, 1:29 PM EST - Market open
bluebird bio Stock Forecast
BLUE's stock price has decreased by -92.23% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 8 analysts with 12-month price forecasts for bluebird bio stock have an average target of 3.03, with a low estimate of 0.50 and a high estimate of 7.00. The average target predicts an increase of 928.51% from the current stock price of 0.29.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for bluebird bio stock from 10 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 4 | 4 | 3 | 3 | 3 | 2 |
| Hold | 5 | 5 | 6 | 6 | 6 | 7 |
| Sell | 2 | 2 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 11 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | +1,257.77% | Nov 15, 2024 |
| B of A Securities | B of A Securities | Strong Buy → Hold Downgrades $3 → $0.5 | Strong Buy → Hold | Downgrades | $3 → $0.5 | +69.72% | Nov 15, 2024 |
| Barclays | Barclays | Buy Maintains $4 → $2 | Buy | Maintains | $4 → $2 | +578.89% | Nov 15, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | +578.89% | Sep 25, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 16, 2024 |
Financial Forecast
Revenue This Year
88.24M
from 29.50M
Increased by 199.14%
Revenue Next Year
252.91M
from 88.24M
Increased by 186.62%
EPS This Year
-1.40
from -1.93
EPS Next Year
-0.67
from -1.40
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 144.6M | 400.8M | 428.4M | ||
| Avg | 88.2M | 252.9M | 298.1M | ||
| Low | 62.7M | 118.6M | 190.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 390.1% | 354.2% | 69.4% | ||
| Avg | 199.1% | 186.6% | 17.9% | ||
| Low | 112.6% | 34.4% | -24.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.00 | 0.05 | -0.89 | ||
| Avg | -1.40 | -0.67 | -0.88 | ||
| Low | -1.68 | -1.20 | -0.86 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.